Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

NCT05382286 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT05382286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05382286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 25, 2022
Completion date
February 28, 2027
Enrollment
443 (actual)
Sites
504

Conditions

As the registry lists them; a condition with its own page is linked.

pd-l1 positive, triple negative breast cancer